A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation

被引:200
作者
Reits, E
Neijssen, J
Herberts, C
Benckhuijsen, W
Janssen, L
Drijfhout, JW
Neefjes, J
机构
[1] Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands
[2] Leiden Univ, Med Ctr, Dept Immunohematol & Blooc Transfus, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1016/S1074-7613(04)00074-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Intracellular proteins are degraded by the proteasome, and resulting peptides surviving cytoplasmic peptidase activity can be presented by MHC class I molecules. Here, we show that intracellular aminopeptidases degrade peptides within seconds, almost irrespectively of amino acid sequence. N- but not C-terminal extension increases the half-life of peptides until they are 15 amino acids long. Beyond 15 amino acids, peptides are exclusively trimmed by the peptidase TPPII, which displays both exo- and endopeptidase activity. Surprisingly, most proteasomal degradation products are handled by TPPII before presentation by MHC class I molecules. We define three distinct proteolytic activities during antigen processing in vivo. Proteasome-generated peptides relevant for antigen presentation are mostly 15 amino acids or longer. These require TPPII activity for further trimming before becoming substrates for other peptidases and MHC class I. The heterogeneous pool of aminopeptidases will process TPPII products into MHC class I peptides and beyond.
引用
收藏
页码:495 / 506
页数:12
相关论文
共 42 条
[1]   Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage [J].
Agami, R ;
Bernards, R .
CELL, 2000, 102 (01) :55-66
[2]   Interferon-γ can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase [J].
Beninga, J ;
Rock, KL ;
Goldberg, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (30) :18734-18742
[3]   Design, synthesis, and tripeptidyl peptidase II inhibitory activity of a novel series of (S)-2,3-dihydro-2-(4-alkyl-1H-imidazol-2-yl)-1H-indoles [J].
Breslin, HJ ;
Miskowski, TA ;
Kukla, MJ ;
Leister, WH ;
De Winter, HL ;
Gauthier, DA ;
Somers, MVF ;
Peeters, DCG ;
Roevens, PWM .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (24) :5303-5310
[4]   Human bleomycin hydrolase: Molecular cloning, sequencing, functional expression, and enzymatic characterization [J].
Bromme, D ;
Rossi, AB ;
Smeekens, SP ;
Anderson, DC ;
Payan, DG .
BIOCHEMISTRY, 1996, 35 (21) :6706-6714
[5]   A system for stable expression of short interfering RNAs in mammalian cells [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
SCIENCE, 2002, 296 (5567) :550-553
[6]   26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide [J].
Cascio, P ;
Hilton, C ;
Kisselev, AF ;
Rock, KL ;
Goldberg, AL .
EMBO JOURNAL, 2001, 20 (10) :2357-2366
[7]   Quantifying recruitment of cytosolic peptides for HLA class I presentation: Impact of TAP transport [J].
Fruci, D ;
Lauvau, G ;
Saveanu, L ;
Amicosante, M ;
Butler, RH ;
Polack, A ;
Ginhoux, F ;
Lemonnier, F ;
Firat, H ;
van Endert, PM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :2977-2984
[8]   Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: A strategy for the design of peptidase inhibitors [J].
Ganellin, CR ;
Bishop, PB ;
Bambal, RB ;
Chan, SMT ;
Law, JK ;
Marabout, B ;
Luthra, PM ;
Moore, ANJ ;
Peschard, O ;
Bourgeat, P ;
Rose, C ;
Vargas, F ;
Schwartz, JC .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :664-674
[9]   A giant protease with potential to substitute for some functions of the proteasome [J].
Geier, E ;
Pfeifer, G ;
Wilm, M ;
Lucchiari-Hartz, M ;
Baumeister, W ;
Eichmann, K ;
Niedermann, G .
SCIENCE, 1999, 283 (5404) :978-981
[10]   A proteolytic system that compensates for loss of proteasome function [J].
Glas, R ;
Bogyo, M ;
McMaster, JS ;
Gaczynska, M ;
Ploegh, HL .
NATURE, 1998, 392 (6676) :618-622